Cell therapy weekly: Anixa Biosciences’ ovarian cancer CAR-T clinical trial begins with treatment of first patient
This week: Anixa Biosciences’ ovarian cancer CAR-T clinical trial begins with treatment of first patient. New era of biomanufacturing announced by Mayo Clinic, in which science, engineering and manufacturing are combined to enhance clinical care. Hemogenyx Pharmaceuticals announce the approval for a Chinese bi-specific antibody patent, as they continue to develop new therapeutic avenues for the treatment of blood diseases.
The news highlights:
-
-
-
-
- New CAR-T clinical trial led by Anixa Biosciences announces treatment of first ovarian cancer patient
- Mayo Clinic will work in concert with National Resilience Inc to advance research and manufacturing within cell and gene therapy areas
- Approval of patent for novel Chinese bi-specific antibody developed by Hemogenyx Pharmaceuticals
-
-
-
New CAR-T clinical trial led by Anixa Biosciences announces treatment of first ovarian cancer patient
Anixa Biosciences (CA, US) announced the lift-off of their joint clinical trial with the Moffitt Cancer Center (FL, US), aiming to evaluate the safety and preliminary efficacy of a novel CAR-T therapy in treating ovarian cancer. However, this Phase I study differs from previous cell therapy efforts. Utilizing a chimeric endocrine receptor T-cell (CER-T) approach, rather than targeting an antigen that may also be expressed by healthy cells, the study aims to target the exclusively ovarian cell expressed follicle stimulating hormone receptor.
Robert Wenham, Chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, commented that “with limited treatment options for recurrent, chemo-resistant ovarian cancer, I am hopeful that this program can provide a unique opportunity to make a meaningful impact on patients of this devastating disease.”
Mayo Clinic will work in concert with National Resilience Inc to advance research and manufacturing within cell and gene therapy areas
Mayo Clinic (MN, US) have set out a new strategy to increase their production and delivery of novel biotherapeutics. This new strategy will primarily focus on increasing the availability of biologics, therapies derived from cells, blood enzymes, genes or other human derived sources. As a part of this aim to advance regenerative technologies, Mayo’s Center for Regenerative Medicine will work alongside National Resilience Inc (CA, US) to gain greater attention from potential sponsors for clinical trials, as well as providing the biologics required for production of these therapies.
Gregory Gores, Kinney Executive Dean of Research at Mayo Clinic, stated that “Mayo Clinic will advance regenerative technologies from discovery science to early phase clinical trials… Research in the emerging field of biotherapeutics lays the foundation to attract the scientific workforce of the future.”
Approval of patent for novel Chinese bi-specific antibody developed by Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals (London, UK) announce the approval of a bi-specific antibody (CDX) for prepping the patient’s blood system prior to a bone marrow transplant. CDX will target a number of proteins present on the surface of hematopoietic stem cells known to seed the development of acute myeloid leukemia. As current conditioning treatments, such as chemotherapy, are extremely intensive and can be harmful to healthy cells, the approval of this patent highlights a step in the right direction in improving survival rates.
Vladislav Sandler, CEO and co-founder of Hemogenyx Pharmaceuticals, commented that “the grant of the patent right on the territory of China is significant for the company because it protects the Company’s IP in one of the largest global markets and further affirms the Company’s leading position in the field of the development of groundbreaking therapies for the treatment of blood cancer and bone marrow/hematopoietic stem cell conditioning.”
You might also like:
